Objective-To examine the associations between baseline levels of fatty acids in blood cell membranes and their 1-year changes with the incidence of coronary heart disease (CHD) in older adults at high cardiovascular disease risk. Approach and Results-This is a case-control study nested in the PREDIMED trial (Prevención con Dieta Mediterránea), with 136 CHD cases and 272 controls (matched on age, sex, body mass index, intervention group, and time of permanence in the study to the time event). We used gas chromatography to measure the proportion of 22 fatty acids in blood cell membranes at baseline and after 1 year. Conditional logistic regression was used to estimate odds ratios (ORs) and 95% CIs. After adjustment for classical CHD risk factors and multiple testing, 1 SD increase in baseline levels of C22:0, C24:0 and the sum of individual very long chain saturated fatty acids was associated with 56% (OR, 0. . Conclusions-Higher levels of C22:0 and C24:0 were associated with a lower CHD incidence, whereas higher levels of C20:1n9 were associated with a higher risk. This study adds to the growing body of evidence suggesting potential differences in the cardiovascular disease effects of different types of circulating saturated fatty acids.
C oronary heart disease (CHD), also known as ischemic heart disease, is the leading cause of death worldwide. 1 CHD incidence is reduced by the appropriate management of risk factors. 2 A meta-analysis summarizing 14 relevant clinical trials showed that 15.4% of women and 19.4% of men with CHD had no classical risk factors. 3 This reinforces the need of identifying novel risk markers for CHD to improve the selection of individuals for preventative strategies.
Fatty acids are integral compounds of cell membrane phospholipids. Rather than merely acting as inert structural elements, fatty acids modulate the physicochemical properties of the membrane and can be converted to bioactive molecules once released from the membrane, having a significant impact on health and disease. 4 In relation to CHD, there is a large body of evidence that long-chain omega-3 fatty acids acylated in cell membranes of cardiomyocytes are the main contributors to myocardial protection on ischemic insult. 5 The omega-3 status in red blood cell membranes is a well-validated surrogate marker for cardiomyocyte membrane omega-3 content. 6 Several prospective studies in Western populations reported significant decreased incident CHD, in particular sudden cardiac death, with increasing omega-3 status in red blood cells, which ultimately fostered its potential as a CHD risk marker. 7 Recent research on CHD and fatty acids expanded beyond omega-3 fatty acids, including fatty acids with absent or marginal endogenous synthesis, in particular essential fatty acids and trans fatty acids, as recently reviewed. 8 In addition, 2 recent large epidemiological studies reported that subjects with high proportions of very long chain saturated fatty acid (VLCSFAs; C20:0, C22:0, and C24:0) in red blood cell membranes had lower risk of sudden cardiac arrest 9 and tended to have lower risk of CHD. 10 However, data on the fatty acid composition of blood cell membrane in relation to CHD incidence are mostly from US cohorts. Taking this into account, the present case-control study, nested in the framework of the PREDIMED trial (Prevención con Dieta Mediterránea), aimed to test for associations between baseline and 1-year changes in the levels of fatty acids of blood cell membranes with incident CHD in a Mediterranean population at high cardiovascular risk.
Materials and Methods
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Study Design and Participants
The present study used a paired-matched case-control design nested within the PREDIMED trial (ISRCTN35739639), a multicenter, single-blinded, controlled trial, conducted in Spanish primary healthcare centers. The PREDIMED trials design has been described in detail elsewhere. 11, 12 This was conducted in 7447 participants at high risk of cardiovascular disease (CVD). Eligible participants were community-dwelling men (55-80 years), and women (60-80 years), who fulfilled at least 1 out of 2 criteria: (1) type 2 diabetes mellitus (T2D) or (2) 3 or more acute coronary syndrome risk factors: current smoking; hypertension (blood pressure >140/90 mm Hg or treatment with antihypertensive drugs); LDL (low-density lipoprotein) cholesterol >160 mg/dL (or treatment with hypolipidemic drugs); HDL (high-density lipoprotein) <50 mg/dL (women) and <40 mg/dL (men); body mass index ≥25 kg/m 2 ; or a family history of premature CHD. Exclusion criteria included: history of CVD, any severe chronic illness, or low predicted likelihood of changing dietary habits according to the stages of change model, among others. Participants were randomly allocated to a Mediterranean diet supplemented with Extra virgin olive oil; a Mediterranean diet supplemented with mixed nuts, or a control diet consisting of advice to reduce fat intake. The Institutional Review Boards of the recruitment centers approved the study protocol, and participants provided written informed consent.
For the present study, we selected CHD incident cases defined by clinical symptoms, electrocardiographic findings, and measurements of biochemical markers. 13, 14 We used 4 sources of information to identify end points: repeated contacts with participants, family physicians, yearly review of medical records, and consultation of the National Death Index. All medical records related to end points were examined by the End Point Adjudication Committee, whose members were blind to intervention allocation. Only end points that were confirmed by the Adjudication Committee and that occurred between October 1, 2003, and December 1, 2010, were considered. 11 We identified a total of 280 incident CHD cases but only 136 cases had available blood cell samples at baseline. Of 136 cases, 27 were stable angina, 65 were unstable angina, and 44 were myocardial infarction. Two controls were selected for each case whereas cases and controls were matched on age, sex, body mass index, intervention group, and time of permanence in the study to the time event. Of those, 211 participants (70 cases and 141 controls) had available samples after 1 year of follow-up and were included in the 1-year change analyses.
Fatty Acid Composition in Blood Cell Membranes
Overnight fasting period (>10 hours) blood samples were obtained by venipuncture and were stored at −80°C until fatty acids analysis. The blood fatty acid profile was determined by gas chromatography as described elsewhere. 15 In brief, cells contained in a 100 μL aliquot of ethylenediaminetetraacetic acid-collected blood were hemolysed and spun. The pellet was dissolved in 1 mL BF 3 methanol solution and heated to hydrolyze and methylate glycerophospholipid fatty acids. The fatty acid methyl esters were isolated by adding n-hexane and were separated by gas chromatography using an Agilent HP 7890 Gas Chromatograph equipped with a 30 m×0.25 μm×0.25 mm SupraWAX-280 capillary column (Teknokroma, Barcelona, Spain), an autosampler, and a flame ionization detector. The amount of each fatty acid was expressed as a percentage of the total identified fatty acids in the sample. As recently stated by Stark et al, 16 expressing fatty acid data in percentage are common because it makes it easier to compare the complex interactions between fatty acids. Total saturated fatty acid (SFA) was the sum of the percentage of C14:0, C16:0, C18:0, C20:0, C22:0, and C24:0. Total monounsaturated fatty acid (MUFA) was the sum of C16:1n7cis, C16:1n7trans, C18:1n9cis, C18:1n9trans, C20:1n9, and C24:1n9. Total n-6 polyunsaturated fatty acid (PUFA) was the sum of C18:2n6, C20:2n6, C20:3n6, C20:4n6, C22:4n6, and C22:5n6. The omega-3 index was calculated as the sum of the percentages of C20:5n3 and C22:6n3. VLCSFAs were the sum of C20:0, C22:0, and C24:0. The method used to quantify the fatty acids has been cross-validated against the method used in the original definition of the omega-3 index, proposed by Harris and Von Schacky.
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Assessment of Other Variables
At baseline, a 47-item questionnaire about lifestyle variables, smoking status, medical history, and medication use was administered. Physical activity was assessed using a validated Spanish version of the Minnesota Leisure-Time Physical Activity Questionnaire. 17 Waist circumference was measured midway between the lowest rib and the iliac crest using an anthropometric tape. Participants' triacylglycerol, total cholesterol, and HDL-C were measured using fasting plasma at baseline. LDL-C levels were calculated by Friedwald formula whenever triacylglycerols were inferior to 300 mg/d. Serum inflammatory markers including IFN (interferon)-γ and ILs (interleukins) IL-1b, IL-6, IL-8, IL-10 were determined using a MILLIPLEX MAP Plex Kit (Merck Millipore, Billerica, MA). T2D was considered to be present at baseline by clinical diagnosis or use of antidiabetic medication.
Statistical Analysis
Baseline characteristics of cases and controls were described as means and SD (normally distributed continuous variables) or median and interquartile range (not normally distributed continuous variables) and percentages or numbers for categorical variables. The amount of each fatty acid is expressed as a percentage of the total identified fatty acids in the sample. A correlation (Spearman) matrix of the fatty acids under study at baseline was visualized through a heat map (R statistical package version 3.1.1; R Development Core Team, 2011; http://cran.r-project.org). The levels of fatty acids and total SFA, VLCSFAs, total MUFA, total n-6 PUFA, LCn-3PUFA, VLCSFAs very long chain saturated fatty acids and Omega-3 index were scaled to multiples of 1 SD. To estimate the association between fatty acids and incident CHD, we used conditional logistic regression model (conditional on the matching). An unadjusted-model and a model adjusted for T2D (yes/no) and smoking (never, current, and former) were fitted. We also examined the associations of 1-year changes in fatty acids with CHD incidence. With respect to fatty acids, we first calculated the difference between 1-year and baseline value and then scaled these differences to multiples of 1 SD. Two-sided P values were reported according to an α level=0.0017 (α=0.05 with Bonferroni correction for 28 independent tests [including 22 individual fatty acids and total SFA, VLCSFAs, total MUFA, total n-6 PUFA, LCn-3PUFA, and Omega-3 index]). Statistical analyses were performed using Stata 14.1 (Stata Corp).
Results
Baseline characteristics of CHD cases and controls are shown in Table 1 . At baseline, participants with incident CHD had a significantly higher T2D prevalence and were more likely to be current smokers compared with controls. Comparisons of fatty acids between cases and controls are displayed in Table I in the online-only Data Supplement. Levels of VLCSFAs, especially C22:0 and C24:0 as well as C22:4n6, C22:5n6, and C24:1n9 were significantly lower in cases than in controls whereas levels of C18:1n9cis and C20:1n9 were higher in cases. Spearman correlation coefficients between baseline and 1-year measures of fatty acids are shown in Table II in the online-only Data Supplement. Figure I in the online-only Data Supplement depicts the correlation matrix of the fatty acids under study at baseline. C22:0 was highly correlated with and C24:0 (Spearman's rank correlation coefficient [rs]=0.87), while C20:1n9 was negatively correlated with these fatty acids (rs=−0.31 and rs=−0.47, respectively). Spearman rank correlations between C22:0, C24:0, VLCSFAs, C20:1n9, and certain food groups are presented in Table III in the online-only Data Supplement. C22:0, C24:0, and VLCSFAs were negatively correlated with nuts consumption, whereas C20:1n9 was positively correlated with fish and olive oil consumption and negatively with dairy products. No significant associations between 1-year changes in fatty acid levels with CHD incidence were found (Table 3) . In cross-sectional analyses adjusted for age (years), smoking (never, current, or former), body mass index (kg/m 2 ), alcohol intake, leisure-time physical activity (metabolic equivalent tasks in minutes per day), and T2D, C22:0 was inversely correlated with IL-10 with Spearman partial correlation coefficients (rs) of −0.16. A similar trend was observed between C24:0 and IL-10 but did not reach the significant level (rs=−0.14). No significant correlations were observed between these 2 VLCSFAs and other inflammatory markers (IFN-γ, IL-1b, IL-6, and IL-8). The C20:1n9 fatty acid was not significantly correlated with any of the aforementioned inflammatory markers. Notably, C22:0 was also inversely correlated with 1-year changes in levels of IL-10 (rs=−0.16, P=0.030) after further adjustment for baseline IL-10. Further cross-sectional analyses adjusted for age (years), sex (men or women), body mass index (kg/m 2 ), smoking (never, current, or former), leisure-time physical activity (metabolic equivalent tasks in minutes per day), dyslipidemia 
Baseline and 1-Year Changes in Fatty Acids and CHD
Discussion
In this case-control study within the PREDIMED trial, we aimed to identify fatty acids in blood cells potentially related to CHD in 408 older adults at high CVD risk. We observed that baseline levels of VLCSFAs and especially C22:0, C24:0 showed significant inverse associations with CHD incidence, independently of smoking and T2D. No significant associations were observed for 1-year changes.
Identifying new biomarkers aiding to reclassify the risk of CHD in populations with a high burden of cardiovascular risk factors is an emerging field in public health. In this regard, our findings reinforce the suitability of blood cell membrane VLCSFAs, in particular C22:0 and C24:0, for this purpose. In addition, our findings suggest that not all SFAs are equal in relation to health and disease, hence contributing to questioning the long-standing dogma of the adverse effects of all types of SFA, regardless of their origin or chemical characteristics. Conditional logistic regression analysis was used. Model 1 is unadjusted. Model 2 adjusted for smoking and diabetes mellitus status that were significantly different between cases (n=136) and controls (n=272). MUFA indicates monounsaturated fatty acid; OR, odds ratio; PREDIMED, Prevención con Dieta Mediterránea; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid; and VLC, very long chain.
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*Remained significant after Bonferroni correction for multiple comparisons.
Our results are in agreement with a recent report from the Nurses' Health Study and the Health Professionals Follow-up Study, in which higher levels of VLCSFAs in plasma and red blood cells were associated with lower risk of CHD. 10 Inverse associations between VLCSFAs in plasma phospholipids and incident atrial fibrillation, 19 and between VLCSFAs in red blood cells and sudden cardiac arrest 9 have also been reported. Our study broadens these studies by extending the findings to an older population at high cardiovascular risk while reproducing them in a much different geographic setting.
The biological mechanisms underlying these observations remain elusive. Most data on circulating fatty acids and CVD relate to fatty acids with absent or marginal endogenous synthesis, namely essential fatty acids, trans fatty acids, and long-chain omega-3 fatty acids, 8 for which membrane status is considered an optimal surrogate marker of their dietary intake. 20 Circulating VLCSFAs may have both dietary and metabolic origin. The former is marginal, being the sources mostly macadamia nuts and peanuts. 21 In our study, VLCSFAs were negatively correlated with nuts consumption and, therefore, circulating VLCSFAs could not be considered as markers of nuts consumption. In contrast, VLCSFAs are easily obtained from the elongation of stearic acid by the action of the elongase elovl1, an enzyme closely linked to the metabolism of sphingomyelins and ceramides. 22 These lipids are found in high concentrations within cell membranes and play an Conditional logistic regression analysis was used. Model 1 is unadjusted. Model 2 adjusted for smoking and diabetes mellitus status that were significantly different between cases (n=70) and controls (n=141). MUFA indicates monounsaturated fatty acid; OR, odds ratio; PREDIMED, Prevención con Dieta Mediterránea; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid; and VLC, very long chain.
important role in membrane function and cellular signaling. 23 Specifically, the VLCSFA content in sphingomyelin may influence the structure/function of lipid rafts, sphingomyelinrich membrane domains where ion channels and signaling molecules are located. In addition, experimental evidence suggests that the VLCSFA content in ceramides has a profound effect on ceramide-induced apoptosis. 24 According to previous animal and cell culture studies, the balance between C16:0 and VLCSFA containing ceramides seems to be the key factor for the induction of apoptosis. 25 Whether C22:0 and C24:0 may lower the risk of metabolic dysfunction and CHD by lowering endogenous levels of ceramides containing shorter SFA 25 is unknown. Interestingly, we found a favorable association between VLCSFAs, C24:0, and T2D which is in line with previous studies 26, 27 and we could speculate that VLCSFAs and especially C24:0 may lower endogenous levels of ceramides containing shorter SFA. 28, 29 However, C22:0 was favorably correlated with a marker of inflammation, IL-10, which has been associated with an increased risk for future cardiovascular events. [30] [31] [32] Further studies are needed to examine this hypothesis, in particular focusing on whether circulating VLCSFA can be modulated through diet. 33 Another member of long-chain fatty acids, C20:1n9 was found to be associated with higher CHD incidence. However, in a previous study, the consumption of macadamia nuts raised plasma concentrations of C20:1n9 and favorably influenced oxidative stress, thrombosis, and inflammation. 34 This long chain monounsaturated fatty acid (LCMUFA) can be derived from the diet 35 and in the present study was directly correlated with both consumption of fish and total olive oil. After adjusting the analyses for fish and total olive oil, our results changed slightly (data not shown) suggesting that the association between this type of LCMUFA and CHD may not be mediated by these foods. Because this LCMUFA can also be formed by de novo synthesis, by the action of fatty acid elongases on oleic acid (C18:1n9), 36 whether higher levels of C20:1n9 in those who developed CHD as compared to the controls indicates increased elongase activity is unknown and requires further work hypotheses and research to be determined.
Contrary to previous studies, [37] [38] [39] we did not find any significant association between omega-3 fatty acids and CHD. Recent studies highlight that there is moderate strength of evidence that marine oil supplementation lowers risk of major adverse cardiovascular events and low strength of evidence that higher marine oil intake is associated with lower risk of CHD and congestive heart failure. 40 Furthermore, moderateand high-quality evidence suggests that increasing eicosapentaenoic acid and docosahexaenoic acid has little or no effect on cardiovascular health (evidence mainly from supplement trials). 41 The results of the present study should be interpreted in the context of its limitations and strengths. First, this is an observational study and causality cannot be established. Second, although we adjusted for T2D and smoking, we cannot exclude the role of residual confounding by unknown factors which weakens our ability to draw causal conclusions. Third, participants were elderly Mediterranean individuals at high cardiovascular risk, and this may limit the generalizability of the findings to other age groups or populations. Strengths include the prospective design and objective measurement of twenty-two individual fatty acids in blood cell membranes.
In conclusion, the results of this study suggest that among older Mediterranean adults at high CVD risk, higher levels of C22:0 and C24:0 are associated with a lower CHD incidence, whereas higher levels of C20:1n9 are associated with higher risk. This study adds to the growing body of evidence, suggesting potential differences in the CVD effects of different types of circulating SFAs. The potential mechanisms linking the aforementioned fatty acids and incident CHD must also be further investigated. 
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